Learn more about whether Biogen Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biogen Inc. (($BIIB)) announced an update on their ongoing clinical study. Biogen Inc. is currently conducting a clinical study titled An ...

C5aR1 plays an important role in the immune cascade that causes tissue inflammation, particularly in neutrophil-mediated conditions. There’s an obvious overlap with Biogen’s own izastobart, an ...

Stoke Therapeutics (STOK) announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with ...

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...

Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United ...

US biotech major Biogen (Nasdaq: BIIB) and RNA medicine specialist Stoke Therapeutics (Nasdaq: STOK) have presented longer-term follow-up analyses from the ongoing open-label extension (OLE) studies ...

Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S.